Quotient Limited to Report Third Quarter 2021 Financial Results and Host Conference Call

Rhea-AI Summary

Quotient Limited (NASDAQ:QTNT) will announce its fiscal third quarter financial results for the period ending December 31, 2020, on February 1, 2021, before market open. A conference call will follow at 8:00 a.m. ET on the same day, accessible via phone and webcast. The company is known for its MosaiQ system, a cutting-edge diagnostics platform that enhances laboratory efficiencies and practices. Notably, Quotient has developed a COVID-19 Antibody Microarray, which is CE marked and has received U.S. FDA Emergency Use Authorization.

Positive

• Quotient's MosaiQ technology is positioned as a game-changing diagnostics solution.
• The MosaiQ COVID-19 Antibody Microarray has received U.S. FDA Emergency Use Authorization.

Negative

• None.

JERSEY, Channel Islands, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2020 will be released before market open on Monday, February 1, 2021.

Quotient will host a conference call to discuss its third quarter financial results at 8:00 a.m. Eastern Time the same day. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The access code is 13715310. The conference call will be webcast live on the Company's website at www.quotientbd.com.

A replay of this conference call will be available through February 8, 2021 by dialing 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S. The replay access code is 13715310.

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

Contact: Peter Buhler, Chief Financial Officer, IR@quotientbd.com; +41 22 545 52 26

FAQ

When will Quotient Limited announce its financial results for Q3 2021?

Quotient Limited will release its Q3 financial results on February 1, 2021.

What time is the Quotient Limited conference call for Q3 results?

The conference call will take place at 8:00 a.m. Eastern Time on February 1, 2021.

How can I access the Quotient Limited conference call?

The conference call can be accessed by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S.

What is the MosaiQ technology developed by Quotient Limited?

MosaiQ is a proprietary multiplex microarray technology that offers a fully automated testing platform for multiple diagnostics.

What is the significance of the MosaiQ COVID-19 Antibody Microarray?

The MosaiQ COVID-19 Antibody Microarray is CE marked and has received U.S. FDA Emergency Use Authorization, indicating its readiness for clinical use.